Arcoxia "Coming Soon" Journal Ads Running As User Fee Date Approaches
This article was originally published in The Pink Sheet Daily
Executive Summary
The ad first appeared in medical journals in early September, well ahead of the Oct. 30 PDUFA date for the COX-2 inhibitor. Merck says the ad does not reflect expectations of a particular FDA review decision but rather is standard industry practice.
You may also be interested in...
Vioxx Label To Add Photosensitivity Reactions As Postmarketing Adverse Event
Supplemental NDA revises labeling for COX-2 inhibitor to include photosensitivity reactions. The Vioxx patient package insert will also be revised to include "skin reactions caused by sunlight."
Symbyax Journal Ad Features Drawing Of Patient Heading "Into The Light"
The reminder ad shows a patient being led by a doctor out of a dense and dark forest into a bright clearing. The spot is part of the product's physician-directed campaign and is not in response to a slower-than-expected launch of the bipolar depression agent, Lilly says.
FDA/Kaiser Study Questions Merck's Vioxx Cardiovascular Safety
Vioxx at doses greater than 25 mg/day is associated with increased risk of acute myocardial infarction and sudden cardiac death, study says. Pfizer's Celebrex had a lower risk of cardiovascular events, the study finds.